What is the appropriate dosing regimen for ubrogepant in adults for acute migraine treatment, including dose adjustments for hepatic or renal impairment?

Ubrogepant Dosing for Acute Migraine Treatment

The recommended dose of ubrogepant is 50 mg or 100 mg taken orally as needed for acute migraine, with a maximum of 200 mg in 24 hours (a second dose may be taken at least 2 hours after the initial dose). 1

Standard Dosing Regimen

• Initial dose: 50 mg or 100 mg orally
• Second dose (if needed): May repeat the same dose at least 2 hours after the initial dose
• Maximum daily dose: 200 mg in any 24-hour period
• Administration: Can be taken with or without food (food delays absorption by 2 hours and reduces peak concentration by 22%, but does not affect overall exposure) 1

Dose Adjustments for Organ Impairment

Hepatic Impairment

Mild hepatic impairment (Child-Pugh Class A):

• No dose adjustment needed
• Ubrogepant exposure increases by only 7% 1, 2

Moderate hepatic impairment (Child-Pugh Class B):

• No dose adjustment needed
• Ubrogepant exposure increases by 50% 1, 2

Severe hepatic impairment (Child-Pugh Class C):

• Reduce dose to 50 mg
• If a second dose is needed, take 50 mg at least 2 hours after the initial dose
• Maximum daily dose: 100 mg (two 50 mg doses)
• Ubrogepant exposure increases by 115% in severe hepatic impairment 1, 2

Renal Impairment

Mild to moderate renal impairment:

• No dose adjustment needed
• Renal elimination plays a minor role in ubrogepant clearance 1

Severe renal impairment (CrCl 15-29 mL/min):

• Reduce dose to 50 mg
• If a second dose is needed, take 50 mg at least 2 hours after the initial dose
• Maximum daily dose: 100 mg (two 50 mg doses) 1

End-stage renal disease (ESRD, CrCl <15 mL/min):

• Avoid use of ubrogepant 1

Clinical Context and Positioning

Ubrogepant is positioned as a CGRP receptor antagonist (gepant) for moderate to severe acute episodic migraine in adults who do not tolerate or have inadequate response to combination therapy of a triptan with an NSAID or acetaminophen 3. The 2025 American College of Physicians guideline recommends considering gepants (including ubrogepant) after first-line therapies have failed 3.

Key Clinical Considerations

Efficacy data: In pivotal trials, 19.2% of patients taking 50 mg and 21.2% taking 100 mg achieved pain freedom at 2 hours (versus 11.8% with placebo), with similar efficacy for freedom from most bothersome symptom 4.

Safety profile: The most common adverse events are nausea, somnolence, and dry mouth (0.4-4.1%), more frequent with the 100 mg dose. Importantly, ubrogepant is not associated with hepatotoxicity at therapeutic doses, unlike earlier gepants 5, 6.

Drug interactions: Ubrogepant is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (e.g., itraconazole) decrease clearance by ~66%, while multiple doses of rifampin increase clearance by 1.82-fold 1, 7. Dose adjustments may be needed with strong CYP3A4 inhibitors or inducers.

Special populations: No dose adjustment is needed based on age, sex, race, or body weight 1, 7. Ubrogepant has not been studied in pediatric patients or adequately in patients ≥65 years 1.